

Rec'd PCT/PTO 13 MAR 2006


PCF

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-262US	
In Re Application Of: GOGIA et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/518,972 ✓		Unknown	26815	Unknown	2913	
Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>						
OR						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-262US

In Re Application of: **GOGIA et al.**



Application No. 10/518,972	Filing Date	Examiner Unknown	Customer No. 26815	Group Art Unit Unknown	Confirmation No. 2913
--------------------------------------	-------------	----------------------------	------------------------------	----------------------------------	---------------------------------

Title: **PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
March 9, 2006 (Date)
 Signature of Person Mailing Correspondence
Christine Kenedy
_____ Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: March , 2006

William D. Hare, Esq.
Reg. No. 44,739

CUSTOMER NO. 26,815

CC:

INFORMATION DISCLOSURE CITATION 	Docket No.: RLL-262US	Serial No.: 10/518,972
	Applicants: GOGIA <i>et al.</i>	
	Filed:	Group:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
S1C1	"Chapter 5: Granulation and Tablet Characteristics" in Leiberman and Lachman, eds. <i>Pharmaceutical Dosage Forms - Tablets, Volume 2</i> . New York: Marcel Dekker, Inc., 185-205 and 261-267 (1981)
S1C2	Summers and Aulton, 2001. "Chapter 25: Granulation" in Aulton, ed. <i>Pharmaceutics: The Science of Dosage Form Design</i> . 2nd Edition. USA: Churchill Livingstone, 364-378.
S1C3	Kassem et al, "Effect of granule size on physical standards of tablets", <i>Manufacturing Chemist and Aerosol News</i> , 24-27 (1972)
S1C4	Yajima et al, "Optimization of Size Distribution of Granules for Tablet Compression ¹⁾ ", <i>Chemical and Pharmaceutical Bulletin</i> , <u>44</u> (5):1056-1060 (1996)
S1C5	Řehula, 1985. "The Effect of Granule Size on Dissolution of Drugs from Tablets" in <i>Universitas Carolina Pragensis, Folia Pharmaceutica VIII</i> . Czechoslovakia:Univerzita Karlova (Charles University), 101-107.
S1C6	Miyamoto et al, "Optimization of the Granulation Process for Designing Tablets", <i>Chemical and Pharmaceutical Bulletin</i> , <u>46</u> (9):1432-1437 (1998)
S1C7	Sheth et al, 1980. "Chapter 3: Compressed Tablets" in Leiberman and Lachman, eds. <i>Pharmaceutical Dosage Forms - Tablets, Volume 1</i> . New York: Marcel Dekker, Inc., 109-185.
S1C8	Planinšek et al, "The utilization of surface free-energy parameters for the selection of a suitable binder in fluidized bed granulation", <i>International Journal of Pharmaceutics</i> , <u>207</u> :77-88 (2000)

EXAMINER	DATE CONSIDERED
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	